Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 7, keine Gesamtzahl für „compared“
Suchtreffer
Begriffe & Kennungen
Prevenar 13 · 4.8 · An increase in vaccination-site reactions was reported in children older than 12 months compared to rates obse
Eintrag öffnenPrevenar 13 · 4.8 · An increase in vaccination-site reactions was reported in children older than 12 months compared to rates obse
Eintrag öffnenProcoralan · 4.8 · In the SIGNIFY study atrial fibrillation was observed in 5.3% of patients taking ivabradine compared to 3.8% i
Eintrag öffnenRaloxifene Teva · 4.8 · In the RUTH study, raloxifene did not affect the incidence of stroke, compared to placebo. However, there was
Eintrag öffnenRaloxifene Teva · 4.8 · Raloxifene (n = 317) was compared with continuous combined (n = 110) hormone replacement therapy (HRT) or cycl
Eintrag öffnenRanexa (previously Latixa) · 4.8 · In patients with mild or moderate renal impairment (creatinine clearance ≥ 30–80 ml/min) compared to those wit
Eintrag öffnenRanexa (previously Latixa) · 4.8 · In patients with mild or moderate renal impairment (creatinine clearance ≥ 30–80 ml/min) compared to those wit
Eintrag öffnenRanexa (previously Latixa) · 4.8 · In patients with mild or moderate renal impairment (creatinine clearance ≥ 30–80 ml/min) compared to those wit
Eintrag öffnenRapiscan · 4.8 · Elderly population Older patients (≥ 75 years of age; n = 321) had a similar adverse reaction profile compared
Eintrag öffnenRatiograstim · 4.8 · No overall differences in safety or effectiveness were observed between subjects over 65 years of age compared
Eintrag öffnenReagila · 4.8 · QT- prolongation With cariprazine no QT interval prolongation was detected compared to placebo in a clinical s
Eintrag öffnenReagila · 4.8 · QT- prolongation With cariprazine no QT interval prolongation was detected compared to placebo in a clinical s
Eintrag öffnenRemicade · 4.8 · Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of pa
Eintrag öffnenRemicade · 4.8 · In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placeb
Eintrag öffnenRemsima · 4.8 · 19 In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of pla
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of pa
Eintrag öffnenRemsima · 4.8 · Immunogenicity Antibodies to infliximab developed in 38% of patients receiving 3 mg/kg compared with 12% of pa
Eintrag öffnenRemsima · 4.8 · In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placeb
Eintrag öffnenRemsima · 4.8 · In clinical studies 36% of infliximab-treated patients were treated for infections compared with 25% of placeb
Eintrag öffnenRevestive · 4.8 · Injection site reactions occurred in 26% of SBS patients treated with teduglutide, compared to 5% of patients
Eintrag öffnen